The present invention relates to compositions consisting essentially of a therapeutically effective amount of a compound selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-isoadhumulone and metformin, to be used in the treatment of an insulin related disorder, diabetes, obesity, or a cardiovascular disease.